Suppr超能文献

嵌合抗原受体T细胞疗法在肝细胞癌治疗中的应用及前景分析:一项系统评价与荟萃分析

Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis.

作者信息

Wu Sichang, Gan Xinli, Huang Shuxin, Zhong Yujun, Wu Jialin, Yang Haojie, Xiang Bangde

机构信息

Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.

The Second Clinical Medical College of Guangxi Medical University, Nanning, China.

出版信息

Front Immunol. 2025 Apr 7;16:1566976. doi: 10.3389/fimmu.2025.1566976. eCollection 2025.

Abstract

INTRODUCTION

Hepatocellular carcinoma (HCC), accounting for 90% of primary liver cancers, is a high-mortality malignancy and the third leading cause of cancer-related deaths globally, with major risk factors like hepatitis B/C, aflatoxin exposure, and obesity. Most patients are diagnosed at advanced stages, with a 5-year survival rate below 10%. Therefore, HCC treatment and research still face significant challenges, and more effective treatments need to be further explored.

METHODS

We searched PubMed, Scopus, Web of Science and Embase from the time of repository construction to March 1, 2025, preliminary included studies involving animal experiments on the therapeutic effects of Chimeric Antigen Receptor T-cell (CAR-T cell) therapy on HCC. After exclusion and evaluation of literature, the random/fixed effects model was employed to perform meta-analysis and obtain Weighted Mean Difference (WMD) and 95% confidence interval (CI) of tumor volume and mass. We then verify the robustness of the results through subgroup analysis and sensitivity analysis. Use Q-test to evaluate heterogeneity and quantify it based on value.

RESULTS

We included a total of 16 studies. Multiple independent sets of data were extracted from the experiments of these studies, of which 25 were used for volume-based meta-analysis and 16 were used for mass-based meta-analysis. Regarding volume, The combined mean CAR-T treatment group/control group resulted in an WMD of -515.77 (95% CI: -634.78 to -396.76; =90.8%). Meanwhile, based on mass, the combined mean CAR-T treatment group/control group resulted in an WMD of -0.30 (95% CI: -0.38 to -0.22; = 94.4%). The results of the bias analysis further validated the reliability of the research conclusions.

CONCLUSIONS

Based on the dual-index meta-analysis, the CAR-T therapy have been proved to possess significant therapeutic effect in HCC. However, the funnel plot of tumor mass and the Egger's regression suggest the potential presence of publication bias. Thus, it warrants further research to evaluate the potential of CAR-T therapy alone or as an adjuvant for HCC treatment.

摘要

引言

肝细胞癌(HCC)占原发性肝癌的90%,是一种高死亡率的恶性肿瘤,也是全球癌症相关死亡的第三大主要原因,主要危险因素包括乙型/丙型肝炎、黄曲霉毒素暴露和肥胖。大多数患者在晚期被诊断出来,5年生存率低于10%。因此,HCC的治疗和研究仍然面临重大挑战,需要进一步探索更有效的治疗方法。

方法

我们检索了从数据库建立到2025年3月1日的PubMed、Scopus、Web of Science和Embase,初步纳入涉及嵌合抗原受体T细胞(CAR-T细胞)疗法对HCC治疗效果的动物实验研究。在对文献进行排除和评估后,采用随机/固定效应模型进行荟萃分析,获得肿瘤体积和质量的加权平均差(WMD)及95%置信区间(CI)。然后通过亚组分析和敏感性分析验证结果的稳健性。使用Q检验评估异质性并基于I²值进行量化。

结果

我们共纳入16项研究。从这些研究的实验中提取了多组独立数据,其中25组用于基于体积的荟萃分析,16组用于基于质量的荟萃分析。关于体积,CAR-T治疗组/对照组的合并平均WMD为-515.77(95%CI:-634.78至-396.76;I² =90.8%)。同时,基于质量,CAR-T治疗组/对照组的合并平均WMD为-0.30(95%CI:-0.38至-0.22;I² = 94.4%)。偏倚分析结果进一步验证了研究结论的可靠性。

结论

基于双指标荟萃分析,CAR-T疗法已被证明对HCC具有显著治疗效果。然而,肿瘤质量的漏斗图和Egger回归提示可能存在发表偏倚。因此,有必要进一步研究评估CAR-T疗法单独或作为HCC治疗辅助手段的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/598c/12009702/023f1d6b494b/fimmu-16-1566976-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验